Oppenheimer & Co. Inc. Takes $212,000 Position in Evolus, Inc. (NASDAQ:EOLS)

Oppenheimer & Co. Inc. bought a new position in Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,113 shares of the company’s stock, valued at approximately $212,000.

Other hedge funds also recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its stake in Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after acquiring an additional 930,566 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Evolus by 24.6% in the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after purchasing an additional 35,760 shares in the last quarter. Armistice Capital LLC bought a new stake in Evolus in the second quarter worth $3,906,000. California State Teachers Retirement System increased its position in Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after purchasing an additional 739 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Evolus by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after purchasing an additional 1,637 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research note on Friday, September 13th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Barclays upped their price objective on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research note on Monday, September 16th.

Evolus Price Performance

EOLS stock opened at $12.60 on Friday. The stock has a market cap of $797.84 million, a PE ratio of -13.85 and a beta of 1.31. Evolus, Inc. has a 12 month low of $9.29 and a 12 month high of $17.82. The company has a 50-day moving average price of $15.68 and a 200 day moving average price of $13.86. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Insider Buying and Selling at Evolus

In related news, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This trade represents a 2.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 6.40 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.